Phase 2 open-label, multicenter clinical study of the safety and efficacy of intravenous administration of SNS-595 [voreloxin] in patients with advanced small cell lung cancer (SCLC)

Trial Profile

Phase 2 open-label, multicenter clinical study of the safety and efficacy of intravenous administration of SNS-595 [voreloxin] in patients with advanced small cell lung cancer (SCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2009

At a glance

  • Drugs Vosaroxin (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Sunesis Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 24 Jul 2007 The expected completion date for this trial is now 1 Jun 2008.
    • 02 Feb 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top